You are here: Industry Insights > msd

News List

HitGen Extends and Expands Research Collaboration and License Agreement with MSD to Build and Screen Novel DNA-Encoded Libraries HitGen
July 30, 2018
July 30, 2018 HitGen Ltd. is pleased to announce that the company has extended and expanded its agreement with MSD, known as Merck & Co., Inc, Kenilworth NJ., USA into a multi-year research collaboration and license agreement to build and screen novel DN
MSD's ulcerative colitis drug scores expanded indication in Europe pharmafile
July 17, 2018
New Jersey-based multinational MSD have announced that the European Commission (EC) has approved Simponi (golimumab) for early dose optimisation in ulcerative colitis (UC) for patients with body weight less than 80kg who do not respond adequately to induc
Final NICE nod for Keytruda in bladder cancer pharmatimes
July 12, 2018
MSD’s Keytruda has become the only immunotherapy to be funded by the NHS for the treatment of bladder cancer, following a final green light from cost regulators.
MSD’s antiviral Prevymis fails to win NICE backing pharmatimes
July 05, 2018
MSD’s Prevymis has not won the support of NHS cost regulators for preventing cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).
AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer pharmafile
June 07, 2018
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza (olaparib) in combination with J&J’s standard-of-care drug Zytiga (abiraterone) in the tre
NICE recommends MSD's Keytruda for advanced PD-L1-positive lung cancer pharmafile
June 07, 2018
UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS for the treatment of previously untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adult patients.
AZ, MSD’s Lynparza/abiraterone combo hits prostate cancer goals pharmatimes
June 06, 2018
AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival (rPFS) in prostate cancer patients taking a combination of Lynparza and abiraterone.
US court upholds verdict voiding MSD's claim to $200m from Gilead in patent dispute pharmafile
April 27, 2018
MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly obtained patent rights for the treatment of hepatitis C, voiding its claim to an infringement verdict against Gilead to the tune of $200 million.
EU reviewing MSD’s Keytruda/chemo combo pharmatimes
April 25, 2018
European regulators have kicked off a review of MSD’s Keytruda/pemetrexed combination for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).
Keytruda prolongs recurrence-free survival in melanoma, study shows pharmatimes
April 17, 2018
MSD and the European Organisation for Research and Treatment of Cancer have released new data showing that the anti-PD-1 therapy Keytruda significantly prolonged recurrence-free survival in patients with high-risk stage III melanoma.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page